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Introduction 
Neurofibromatosis (von Recklinghausen’s disease) 
is an autosomal-dominant, inherited disorder. Both 
sexes are affected equally (1,2). The disease is 
characterized by multiple neurofibromas which can 
arise in any organ system. Most of the patients 
belong to the more common type I (formerly called 
classical or peripheral form with ‘cafe-au-lait’ spots, 
multiple neurofibromas, Lisch nodules found in the 
iris, and other changes of the skeletal or neural 
system), less patients are grouped under the rare type 
II (formerly called central or acoustic form), and a 
few patients cannot be separated clearly into one of 
the two types (2,3). 
Co-existing pulmonary fibrosis and/or cystic lung 
disease and neurofibromatosis have been noted since 
1928 (4,5). Sporadic reports on pulmonary changes 
have been published in about 50 patients with neuro- 
fibromatosis (4-16). Three larger studies showed 
diffuse pulmonary fibrosis in lo-30% of adults with 
the disorder (5,7,9). Although neurofibromatosis is 
congenital, pulmonary fibrosis does not appear until 
adulthood. 
To the best of the authors’ knowledge, broncho- 
alveolar lavage (BAL) cellular findings have not been 
reported previously in this disorder. 
Case Report 
A 48-year-old woman was hospitalized with mildly 
progressive dyspnoea on exertion, and sporadic 
cough with moderate sputum production for 2 yr. 
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She had been smoking 40 cigarettes day- ’ for 30 yr. 
There was no exposure to dusts. 
Physical examination revealed at least seven ‘cafe 
au lait’ patches, axillary freckling, and multiple 
typical neurofibromas over the trunk. Fine, late 
inspiratory crackles were audible over the right lung 
base. The chest radiograph showed micronodular 
infiltrates involving mainly the lower zones on both 
sides. The computerized tomographic (CT) scans 
showed reticular shadowing with some ground glass 
densities in the upper zones, and more extensive 
opacities with subpleural bullous lesions in the lower 
zones. Laboratory studies disclosed a mildly elevated 
sedimentation rate of 16 mm h ~ ‘, and a y-GT of 
48 U 1~ i (normal range 4-18 U l- ‘). Other values 
were within normal limits. Skin prick tests for the 
most common allergens and precipitins against bird, 
aspergillus and farmer’s lung antigens were negative. 
Lung function tests showed mild obstruction with a 
vital capacity (VC) of 2.91 (73% predicted), total lung 
capacity 6.51 (114% predicted), residual volume 3.61 
(211% predicted) and FEV,NC 52% (70% predicted). 
Airways resistance was normal. After p-agonist 
inhalation, there was no significant increase in FEV,. 
Measurements of arterial blood bases at rest revealed 
a PaO, of 66 mmHg (8.8 kPa) and a PaCO, of 
34 mmHg (4.4 kPa). PaO, at exercise (30 W) dropped 
to 59 mmHg (7.8 kPa); PaCO, remained at 34 mmHg 
(4.4 kPa). 
Fibre-optic bronchoscopy disclosed no abnor- 
malities. Bronchoalveolar lavage was performed with 
5 x 20 ml saline in the lateral segment of the middle 
lobe, and fractions were pooled before analysis. Cell 
smears were stained with May-Grtinwald-Giemsa 
stain and revealed an elevated fraction of 7% 
eosinophils and a mild increase in mast cells (see 
Table 1). Open lung biopsy was performed in 
the anterobasal segment of the lower lobe. The 
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Table I Bronchoalveolar lavage fluid cytology 
Normal smokers 
Patient (n= 15) 
Fluid recovery (ml) 
Total cells ( x 106) 
Cell differentials 
Macrophages (%) 
( X lo3 ml-‘) 
Lymphocytes (%) 
(x 103ml-‘) 
Neutrophils (%) 
(X 103mll’) 
Eosinophils (%) 
(X 103mll’) 
Mast cells (%) 
( X lo3 ml-‘) 
40 53 * 14 
25 28zk 15 
83.4 95 f 3 
520.0 531* 334 
6.6 3*2 
41.3 16.6 * 12.8 
2.0 lZt1 
12.5 1 l-5 f 14.3 
7.0 0.4 f 0.5 
43.8 2.29 zk 7.8 
1.1 0.1 + 0.3 
6.9 0.9 zlz 2.0 
Values are means * so. 
histological features were consistent with pulmonary 
fibrosis with subpleural predominance. The alveolar 
walls were thickened due to fibrous tissue prolifer- 
ation. There was only mild interstitial inflammation 
with scattered lymphocytic accumulation and mini- 
mal irregular emphysema. Eosinophils and mast cells 
were not predominant. Pneumocytes showed cubic 
transformation. There were no honeycomb transfor- 
mation, vascular changes or abnormal neural 
proliferations. 
Despite treatment with prednisone for 3 months, 
and combined prednisonelazathioprine for another 3 
months, the disease was progressive. The patient, 
who had continued smoking, was next placed on 
prednisone 20 mg and cyclophosphamide 125 mg 
daily. Ten months later, her lung function showed a 
slight improvement. 
Discussion 
To the authors’ knowledge, this is the first study on 
BAL findings in pulmonary fibrosis associated with 
neurofibromatosis. Interestingly, the BAL cell differ- 
ential showed a mild eosinophilic alveolitis, as may 
be seen in some patients with idiopathic pulmonary 
fibrosis. In addition, the mast cells were increased 
slightly. These cells were not predominant in the lung 
biopsy. However, discrepancies between BAL and 
histology regarding the profile of inflammatory cells 
are not unusual. However, although it has been 
pointed out that there are no specific histological 
changes in pulmonary fibrosis in neurofibromatosis 
type I, most investigators describe large apical bullae 
with interstitial changes (6,7,15), or comparable 
findings to those seen in diffuse fibrosing alveolitis 
(6,7,9). 
The pathogenesis of the disorder remains 
unknown. One possible explanation would be an 
inherited mesenchymal defect resulting in the 
immediate deposition of collagen (8). This view is 
supported by the observation of fibrous tissue pro- 
liferation in other mesenchymal tissues, e.g. bone or 
blood vessels, in neurofibromatosis (17-19). More 
recently, the role of mast cells for the manifestation 
of skin lesions in neurofibromatosis has been empha- 
sized (20). As neurofibromas contain a large number 
of mast cells able to release heparin and histamine, 
mast cell stabilization has been suggested as a thera- 
peutic ppssibility to reduce neurofibroma growth and 
pruritus (20). In this respect, it is of interest that the 
BAL fluid of the present patient contained an 
increased proportion of mast cells. Whether these 
mast cells are protagonists in the pathogenesis of 
pulmonary fibrosis in neurofibromatosis should be 
subject of future studies. 
In conclusion, the BAL fluid of this patient with 
pulmonary fibrosis and neurofibromatosis revealed a 
mild increase in eosinophils and mast cells. Both cell 
types may play a role in the pathogenesis of the 
disorder. 
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